Descripción de la empresa
Cassava Sciences Inc. operates within the healthcare sector, specifically functioning as a clinical-stage biotechnology firm dedicated to the development of therapeutic interventions for neurodegenerative diseases. The company focuses on advancing drug candidates, such as simufilam, a small molecule compound that has completed Phase 2 clinical trials, alongside investigational diagnostic tools like SavaDx, which is designed as a blood-based diagnostic product. In terms of market scale, Cassava Sciences holds a market capitalization of $114.97M, employs a workforce of 30 individuals, and reports no disclosed annual revenue figures in the current financial data. The market capitalization of $114.97M indicates that the company possesses a mid-cap profile typical of early-to-mid stage biotechnology entities, where valuation is driven primarily by pipeline potential and clinical progress rather than established revenue streams, while the absence of reported revenue highlights the pre-commercial nature of its business model at this stage of development.
Salud financiera
The company reports a net income of $-106,031,000 and an EBITDA of $-69,296,000 over the trailing twelve months, with revenue figures listed as N/A due to its current stage of commercialization. The significant gap between the reported revenue status and the substantial net loss reveals a cost structure dominated by research and development expenditures typical for a clinical-stage biotechnology company, where capital is heavily invested in advancing assets through regulatory milestones rather than generating immediate profit. Despite the net loss, Cassava Sciences maintains a free cash flow of $18.57M, a figure that signifies a degree of financial flexibility allowing the company to fund its operations and clinical programs without relying exclusively on external equity financing. The gross margin, operating margin, and profit margin are all recorded at 0.0%, which indicates that the company has not yet achieved profitable operations on a GAAP basis, consistent with the accounting treatment of R&D expenses and the lack of commercial sales. On the balance sheet, the company holds cash totaling $106.08M against a debt level listed as N/A, suggesting a conservative capital structure with no reported leverage obligations. This liquidity position is further supported by a current ratio of 2.27, which indicates strong short-term liquidity and the ability to cover current liabilities more than twice over using current assets. Return on Equity stands at -85.4% and Return on Assets at -24.8%, metrics that reveal management is currently utilizing shareholder and company assets to generate negative returns as the firm invests heavily in its clinical pipeline before reaching commercial profitability.
Evaluación de valoración
Cassava Sciences exhibits a P/E Ratio (TTM) listed as N/A due to its lack of positive earnings, while the Forward P/E is calculated at -1.34, implying that the market anticipates continued losses or a specific earnings trajectory that results in a negative valuation multiple relative to projected forward earnings. The price-to-book ratio is 1.41, indicating that the market values the company at 41% above its book value, which suggests a market premium attributed to the potential value of its intellectual property and clinical pipeline assets rather than its tangible book value. Alternative valuation metrics such as the price-to-sales ratio, which is N/A due to the absence of sales data, and the EV/EBITDA of 0.07, provide context for a company that cannot be valued using traditional earnings-based multiples, as the low EV/EBITDA reflects the high cash position relative to negative earnings. The stock's 52-week high is $4.98 and the 52-week low is $1.15, placing the current trading environment within a volatile range that fluctuates significantly based on clinical trial results and broader biotechnology sector sentiment. The beta value of -0.84 indicates a price volatility that moves inversely to the broader market, meaning the stock tends to rise when the market falls and vice versa, presenting a unique risk profile for a financial portfolio seeking diversification.
Growth & Income
Cassava Sciences reports revenue growth (YoY) and earnings growth (YoY) both as N/A, reflecting the company's status as a pre-revenue entity where traditional growth metrics based on year-over-year sales comparisons are not yet applicable to its business model. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which indicates that the firm reinvests all available resources and cash reserves into research, development, and clinical trial expansion rather than distributing income to shareholders. This reinvestment strategy is characteristic of biotechnology firms in the clinical stage, where the primary objective is to advance drug candidates like simufilam through regulatory hurdles to achieve commercialization. Consequently, the overall growth and income profile of Cassava Sciences is defined by a reliance on capital markets for funding and a focus on clinical milestones rather than current revenue generation or dividend income for investors.